DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,044,466 B2 Cohen Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,044,466 B2 Cohen Et Al USOO9044466B2 (12) United States Patent (10) Patent No.: US 9,044,466 B2 Cohen et al. (45) Date of Patent: *Jun. 2, 2015 (54) ORAL COMPOSITIONS COMPRISINGA 2800/882 (2013.01); A61O II/00 (2013.01); ZINC COMPOUND AND AN A61K 45/06 (2013.01); A61 K47/02 (2013.01); ANT-MICROBAL AGENT (Continued) (58) Field of Classification Search (75) Inventors: Marvin Cohen, St. Louis, MO (US); CPC ...... A61K 8/27; A61 K33/30; A61K 31/4425 Susanne Cohen, St. Louis, MO (US); USPC ............................................................ 424/49 Robert G. Flynn, Dupo, IL (US) See application file for complete search history. (73) Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF (56) References Cited NEW YORK, Albany, NY (US) U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this 4,226,851 A 10/1980 Sompayrac patent is extended or adjusted under 35 4,692,262 A 9, 1987 Brown et al. U.S.C. 154(b) by 0 days. (Continued) This patent is Subject to a terminal dis claimer. FOREIGN PATENT DOCUMENTS CN 101780016 A T 2010 (21) Appl. No.: 13/204,595 WO WO-OOf 51559 A1 9, 2000 (22) Filed: Aug. 5, 2011 (Continued) OTHER PUBLICATIONS (65) Prior Publication Data International Preliminary Report on Patentability for International US 2012/003428O A1 Feb. 9, 2012 Application No. PCT/US2011/046831 dated Feb. 21, 2013. Related U.S. Application Data (Continued) (60) Provisional application No. 61/371,695, filed on Aug. Primary Examiner – Rachael E. Bredefeld 7, 2010, provisional application No. 61/371,696, filed (74) Attorney, Agent, or Firm — Harness, Dickey & Pierce, on Aug. 7, 2010. P.L.C. (51) Int. Cl. (57) ABSTRACT A6 IK 8/27 (2006.01) A6 IK33/30 (2006.01) Oral compositions and methods of use thereofare provided herein. The oral compositions comprise a first component (Continued) comprising at least one E-raising compound and a pharma (52) U.S. Cl. ceutically acceptable carrier, and a second component com CPC ................. A61K 31/435 (2013.01); A61K 8/20 prising at least one Zinc compound, an anti-microbial agent (2013.01); A61K 8/22 (2013.01); A61K 8/27 and a pharmaceutically acceptable carrier. (2013.01); A61K 8/368 (2013.01); A61 K 8/4926 (2013.01); A61K 8/922 (2013.01); A61 K 40 Claims, 4 Drawing Sheets (S Water) US 9,044,466 B2 Page 2 (51) Int. Cl. (56) References Cited A6 IK3I/4425 (2006.01) A6 IK9/08 (2006.01) U.S. PATENT DOCUMENTS A6 IK 8/22 (2006.01) 5,174.990 A 12/1992 Douglas A6 IK33/40 (2006.01) 5,576,299 A * 1 1/1996 Ando et al. .................... 514/25 5,958,984 A 9, 1999 Devillez A6 IK 8/20 (2006.01) 6,409,992 B1 6/2002 Kleinberg et al. .............. 424/49 A6 IK 47/10 (2006.01) 6,423.300 B1 7/2002 Kleinberg et al. .............. 424/49 6,723,305 B2 4/2004 DePierro et al. ................ 424.54 A6 IK 47/02 (2006.01) 6,929,790 B2 8/2005 Kleinberg et al. .............. 424/49 A6 IK33/20 (2006.01) 2002fO150630 A1 10, 2002 Brooks et al. A6 IK 8/II (2006.01) 2006/0171907 A1 8, 2006 Scott et al. 2007,0292531 A1 12/2007 Clarot et al. A6 IK 8/02 (2006.01) 2013/0164358 A1 6, 2013 Cohen et al. A6 IK 8/49 (2006.01) A 6LX8/97 (2006.01) FOREIGN PATENT DOCUMENTS A6 IK 8/98 (2006.01) WO WO-2007, 134335 A2 11/2007 A61O II/00 (2006.01) WO WO-2009,099.454 A1 8, 2009 A6 IK3I/435 (2006.01) OTHER PUBLICATIONS A6 IK 8/368 (2006.01) International Search Report and Written Opinion dated Oct. 23, 2012 A6 IK 8/92 (2006.01) issued in International Application No. PCT/US2011/046831. Office Action dated Sep. 5, 2014 issued in U.S. Appl. No. 13/814,070. A6 IK 45/06 (2006.01) Office Action dated Jan. 29, 2015 issued in U.S. Appl. No. A6 IK9/00 (2006.01) 13/814,070. (52) U.S. Cl Office Action dated Feb. 12, 2015 issued in U.S. Appl. No. CPC .............. A61K 47/10 (2013.01); A61K 9/0063 Rölla,ER." G. etal. (2002), “The significance of the source of zinc and its (2013.01); A61K 9/08 (2013.01); A61 K anti-VSC effect”, Int. Dent J., 22(52): 233-235. 31/4425 (2013.01); A61K 33/20 (2013.01); A61 K33/30 (2013.01); A61 K33/40 (2013.01) * cited by examiner U.S. Patent Jun. 2, 2015 Sheet 1 of 4 US 9,044,466 B2 (S. Water) Fig. 1 U.S. Patent Jun. 2, 2015 Sheet 2 of 4 US 9,044,466 B2 (S2 L isterine)s Fig. 2 U.S. Patent Jun. 2, 2015 Sheet 3 of 4 US 9,044,466 B2 (SSM) Fig. 3 U.S. Patent Jun. 2, 2015 Sheet 4 of 4 US 9,044,466 B2 (S, SM ACF) Fig. 4 US 9,044,466 B2 1. 2 ORAL COMPOSITIONS COMPRISINGA alveolar bone. Severe periodontitis resulting in deep peri ZINC COMPOUND AND AN odontal pockets may ultimately result in tooth loss. ANT-MICROBAL AGENT Previous studies have largely focused on the use of germi cidal agents to treat gingivitis-periodontitis and oral malodor. CROSS-REFERENCE TO RELATED These studies have not recognized that gingivitis-periodonti APPLICATIONS tis and oral malodor arise from a common process, namely oral bacterial putrefaction; and also that this putrefaction can This application claims the benefit of U.S. Provisional be inhibited by simultaneously lowering the ability of the oral Application No. 61/371,695 filed on 7 Aug. 2010 and U.S. bacteria to reduce the oxidation-reduction potential (E) of Provisional Application No. 61/371,696 filed on 7 Aug. 2010. 10 the oral cavity and at the same time, raising the existing E, to The disclosure of each of the applications identified in this where the oral environmental E, is not conducive to oral paragraph is incorporated herein by reference in its entirety. putrefaction and oral disease production. U.S. Pat. No. 6,929,790 to Kleinberg et al., which is a FIELD 15 continuation application of U.S. Pat. No. 6,423.300 which is a divisional application of U.S. Pat. No. 6,409,992, reports an The present disclosure relates generally to oral composi oral composition comprising a Zinc compound and at least tions, oral care systems and methods of using the same. More one E, raising compound. particularly, the present disclosure relates to oral composi U.S. Pat. No. 6,723.305 to DePierro et al. reports an oral tions comprising at least one Zinc compound and at least one composition comprising a Zinc compound and CPC. E-raising compound, and methods of using the same. In a particular embodiment, cetylpyridinium chloride (CPC), SUMMARY CHNC1, is also included in the oral composition. This section provides a general Summary of the disclosure, BACKGROUND 25 and is not a comprehensive disclosure of its full scope orall of its features. This section provides background information related to Generally, an oral composition is provided herein. The oral the present disclosure which is not necessarily prior art. composition is capable of inhibiting the formation of sulfur The hard and soft tissues of the mouth are covered with containing compounds, reducing oral malodor and gingivitis, microbial populations that include bacteria having different 30 reducing the formation of dental caries, inhibiting plaque metabolic capabilities where the microbial populations may formation and reducing the formation of plaque and tartar include both Gram-positive bacteria and Gram-negative bac (calculus). Further, an oral care system comprising an oral teria. Generally, Gram-positive aerobic bacteria readily composition described herein is also provided. catabolize carbohydrates to produce acids which attack the In one embodiment, there is provided an oral composition hard tissues of the oral cavity, and which over time may result 35 comprising: a first component comprising at least one E in the formation of dental carious lesions (cavities). In con raising compound and a pharmaceutically acceptable carrier, trast, Gram-negative anaerobic bacteria readily metabolize and a second component comprising at least one Zinc com various amino acids included in salivary peptides and pro pound, cetylpyridinium chloride (CPC) and a pharmaceuti teins to form end-products which favor a formation of oral cally acceptable carrier. malodorand gingivitis-periodontitis. This process of peptide, 40 In a particular embodiment, the first and second compo protein and amino acid degradation by the mouth bacteria is nents are stored separately. referred to as oral bacterial putrefaction. The mixture of mal In some embodiments, the oral composition further com odorous compounds produced by the Gram-negative anaero prises xylitol and/or other oral health ingredients. bic bacteria during putrefactive degradation of proteins, pep In yet another embodiment there is provided a method for tides and amino acids include hydrogen Sulfide, methyl 45 reducing oral malodor, treating oralleviating dental diseases, mercaptan, and dimethyl sulfide (formed from the sulfur reducing plaque and reducing canker Sores. The methods containing amino acids cysteine, cystine and methionine); comprise delivering the oral composition to an oral cavity in indole and skatole (formed during the metabolism of tryp a Subject. The Subject may be human or a non-human animal. tophan); cadaverine and putrescine (produced from lysine Further areas of applicability will become apparent from and ornithine); and butyrate and Valerate (produced from the 50 the description provided herein. The description and specific metabolism of other amino acids). The production of these examples in this Summary are intended for purposes of illus malodorous compounds in the oral cavity results in a condi tration only and are not intended to limit the scope of the tion commonly referred to as oral malodor.
Load more

Recommended publications
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • IV. CONTENTS of the 9Th EDITION
    EUROPEAN PHARMACOPOEIA 9.0 Contents of the 9th Edition IV. CONTENTS OF THE 9th EDITION The 9th Edition consists of new texts as well as all current Lines in the margin that were present in revised or corrected texts from the 8th Edition, some of which have been revised texts in the previous edition are deleted with each new edition. or corrected. From the 9th Edition, corrections that are indicated by the note Lists of the monographs and general chapters that, for the ‘corrected X.X’ under the version date are to be taken into 9th Edition, are new, revised or corrected, have undergone accountassoonaspossibleandnotlaterthantheendofthe pharmacopoeial harmonisation or have had their titles month following the month of publication of the volume. th changed, are given below. From the 9 Edition, a barcode is included at the start of each text, providing a link to further information on the text The version date (for example 01/2017 for a text that is new or (e.g. the Knowledge database) for smartphones and tablets revised for the 9th Edition), completed by ‘corrected X.X’ if a withacameraandabarcodereaderapp. corrected version of the text has subsequently been published For the 9th Edition, the following decisions and systematic in Supplement X.X, and the reference number (4 digits for modifications to the texts of the European Pharmacopoeia monographs and 5 digits for general chapters) are specified have been made. abovethetitleofeachmonographandgeneralchapter.The – Tests for heavy metals have been deleted from the version date, completed by ‘corrected X.X’ if appropriate, monographs concerned (see under ‘Useful information’ in makes it possible to identify the successive versions of texts in Pharmeuropa Online).
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Lista De Productos En Orden Alfabético
    FARMACÉUTICO QUÍMICO VETERINARIO COSMÉTICO Lista de productos en orden alfabético ALUMINIUM SULPHATE A AMBROXOL HCL AMBROXOL HCL PELLETS 25% AMIFOSTINE ABACAVIR AMILORIDE HCL ABACAVIR SULPHATE AMINACRINE HYDROCHLORIDE ACEBROPHYLLINE AMINOPHYLLINE ACEBUTOLOL HCL AMITRIPTYLINE EMBONATE ACECLOFENAC AMITRIPTYLINE HCL ACEFYLLINE AMITRIPTYLINE N OXIDE ACEFYLLINE PIPERAZINE ORAL AMLA EXTRACT ACEFYLLINE PIPERAZINE - STERILE) AMLODIPINE BESYLATE ACENOCOUMAROL (NICOUMALONE) AMLODIPINE MALEATE ACEPHATE TECHNICAL AMLODIPINE MESYLATE ACEPHYLLINE PIPERAZINE AMMONIUM ACEPIPHYLLINE / ACEPIFYLLINE AMMONIUM ACETATE ACETAMINOPHEN/PARACETAMOL AMMONIUM CHLORIDE ACID YELLOW 73 AMMONIUM DICHROMATE ACITRETIN AMMONIUM HYPOPHOSPHATE ACRIFLAVINE HYDROCHLORIDE AMMONIUM IODIDE ACRIFLAVINE NEUTRAL AMMONIUM PHOSPHATE DIBASIC ACRINOL AMMONIUM PHOSPHATE MONOBASIC ALUMINIUM OXIDE AMMONIUM SULPHATE ACTIVATED CHARCOL AMOMUM SUBULATUM ACYCLOVIR AMOXAPINE ACYCLOVIR SODIUM AMOXYCILLIN TRIHYDRATE ADAPALENE AMPICILLIN ANHYDROUS ADEFOVIR DIPIVOXIL AMPICILLIN SODIUM AND SULBACTAM SODIUM ADHATODA VASICAL LEAF AMPICILLIN SODIUM+SULBACTAMSODIUM AEGLE MARMELOUS FRUIT AMPICILLIN TRIHYDRATE AGOMELATINE AMPIROXICAM AJOWAN SEED OLEORESIN AMPRENAVIR AJOWAN OIL ANACYCLUS PYRETHRUM ALBENDAZOLE ANAGRELIDE HCL ALBUTEROL SULPHATE ANAGRELIDE HCL MONOHYDRATE GAMMA UNDECALACTONE ANASTRAZOLE ALENDRONATE SODIUM ANDROGRAPHATIS ALFUZOSIN ANDROGRAPHIS PANICULATA ALFUZOSIN HCL ANDROGRAPHOLIDE ALLIUM CEPA BULBS ANESTHETIC ETHER ALLIUM SATIVUM BULBS ANILINE HYDROCHLORIDE ALLYL HEPTANOATE ANISE OIL ALMAGATE
    [Show full text]
  • Medicines Used Across Wirral Health Economy
    Medicines used across Wirral Health Economy Below is a list of medicines that are approved for use on Wirral. Some medicines may only be prescribed in hospital, others may be prescribed by your GP. The list is updated every time a new medicine is approved for use in Wirral. Some medicines have been recommended by the National Institute for Health and Care Excellence (NICE). The second column of the table below indicates recommendations made by NICE — eg, TA234 means that the medicine was reviewed in NICE technology appraisal number 234. Some of the medicines we use are recommended by specialists working from other hospitals e.g. Walton Centre NHS Foundation Trust, Cheshire and Wirral Partnership NHS Foundation Trust and Alder Hey Children’s NHS Foundation Trust. These medicines are included in our formulary — however; the prescriber retains responsibility for the appropriate use of these medicines. These formularies are obtainable here: Pan Mersey Formulary (For Walton Centre and Alder Hey) Cheshire and Wirral Partnership Formulary All medicines listed are approved in all licensed formulations unless otherwise specified. Please see separate list for adults enteral and supplementary feeds. Drug Name Subject to NICE recommendation 50% liquid paraffin / 50% white soft paraffin Abatacept TA195, TA373, TA375 Acamprosate Acarbose Accu-Chek Inform II® AccuSol® 35 Potassium 4mmol/L Acencoumarol Acetazolamide Acetic acid 5% solution Acetone Acetylcysteine injection Aciclovir Wirral Medicines Formulary Author: Medicines Management Team Approved
    [Show full text]
  • United States Patent (19) (11) 4,397,837 Raaf Et Al
    United States Patent (19) (11) 4,397,837 Raaf et al. 45) Aug. 9, 1983 (54) PROCESS AND COMPOSITION FOR THE 3,679,360 1/1972 Rubin et al. .................... 424/128 X REMNERALIZATION AND PREVENTION OF DEMINERALZATION OF ANIMAL FOREIGN PATENT DOCUMENTS TEETH INCLUDINGHUMANS 1090340 11/1967 United Kingdom. 75 Inventors: Helmut Raaf, Karlsruhe-Waldstadt; OTHER PUBLICATIONS Helmut Harth, Mainz; Helmar R. Wagner, Darmstadt-Arheilgen, all of Souder et al., J. Am. Dental. Assoc., 31, No. 23, Fed. Rep. of Germany (12/1/44), pp. 1579–1586. Public Health Reports, 63, No. 38, 9/17/48, pp. 73) Assignee: Blendax-Werke R. Schneider GmbH 1215-1221. & Co., Mainz, Fed. Rep. of Germany Feagin et al., Arch. Oral Biology, vol. 16, pp. 535-548, 21 Appl. No.: 540,862 (1971). (22 Filed: Jan. 14, 1975. Primary Examiner-Douglas W. Robinson Attorney, Agent, or Firm-Connolly and Hutz Related U.S. Application Data (57) ABSTRACT 63 Continuation of Ser. No. 327,466, Jan. 29, 1973, aban Compositions for the remineralization and prevention doned. of demineralization of the teeth of animals including (30) Foreign Application Priority Data humans in the form of two phases, one phase containing a water-soluble calcium compound and the other phase Feb. 2, 1972 GB United Kingdom ................. 4848/72 containing a water-soluble phosphate and optionally a 51 Int. Cl.......................... A61K 7/16; A61K 7/18; water-soluble fluorine compound. The concentration of A61K 23/42; A61K 33/16 calcium and phosphate (PO4) ions is about 50 to 35,000 52 U.S.C. ........................................ 424/51; 424/52; ppm and 50 to 40,000 ppm respectively, and the amount 424/57; 424/128; 424/151; 424/154 of fluorine compound is about 0.01 to 5.0%, all by 58) Field of Search ......................
    [Show full text]
  • Product Overview
    Pharmacin Sourcing Global sourcing service, from suppliers and products you can trust. Pharmacin was founded in 1986 and has been active in the field of pharma- If you require a product that is not listed in our enclosed raw material ceutical raw materials. In 2006, Pharmacin has become a 100% subsidiary overview, our expertise and Aurobindo’s worldwide network allow us to Aurobindo Pharma Ltd. Aurobindo is one of the top API manufacturing act like a virtual manufacturing company. We source globally for the raw compa nies in the world and also among the very few pharmaceutical materials to meet your specific requirements. companies that are vertically integrated with a presence in API and for- mulations segments and delivering innovative solutions. All of our activities are in line with current GMP/GDP directives. Pharmacin is fully compliant with the Falsified Medicines Directive and we only approve Pharmacin’s strength is the ability to seamlessly switch between the wide suppliers that have successfully completed the Pharmacin supplier qua- variety of customer requirements and actual production capability. With lification process. This way, we ensure safe and controlled trading. We a range of more than 1000 raw materials – from Active Pharmaceuti- have GMP classified cleanrooms for the conditioning of raw materials cal Ingredients (APIs) and excipients to herbs to extracts – Pharmacin into any size you require. provides solutions for the pharmaceutical, veterinary, food and cosmetic industry. Committed to a healthier life Pharmacin
    [Show full text]
  • Alphabetical Listing by Therapeutic Category Dod UNIFORM
    DoD UNIFORM OUTPATIENTFORMULARY Alphabetical Listing by Therapeutic Category This document is current as of July 14, 2021 The availability of formulary items is subject to change. 1 ABORTIFACIENT Abortifacient Dextromethorphan and Chlorpheniramine .............................................35 Carboprost Tromethamine ..................................................................... 23 Hydrocodone and Chlorpheniramine ..................................................... 60 Dinoprostone .......................................................................................... 37 Ibuprofen, Phenylephrine, and Chlorpheniramine ................................. 62 MiFEPRIStone ........................................................................................81 Ibuprofen, Pseudoephedrine, and Chlorpheniramine ............................ 62 Naphazoline and Pheniramine ...............................................................83 Acetylcholinesterase Inhibitor Triprolidine ............................................................................................ 116 Echothiophate Iodide ............................................................................. 40 Triprolidine and Pseudoephedrine ....................................................... 117 Edrophonium .......................................................................................... 40 Edrophonium and Atropine .................................................................... 41 Allergen-Specific Immunotherapy Neostigmine ............................................................................................84
    [Show full text]
  • Atc Index 2010
    ATC INDEX 2010 This is a version of the World Health Organization (WHO) ATC index and, as such, contains some substances for which data are not available in the two tables. This ATC index is sorted alphabetically according to generic/substance International Nonproprietary Name (INN). There may be some variance in the spelling of the generic name. 287 A L 04 A B 04 Adalimumab A 03 A B 16 (2-benzhydryloxyethyl) D 10 A D 03 Adapalene diethyl-methylammonium iodide D 10 A D 53 Adapalene, combinations D 01 A E 06 2-(4-chlorphenoxy)- ethanol J 05 A F 08 Adefovir dipivoxil V 03 A B 27 4-dimethylaminophenol A 16 A A 02 Ademetionine J 05 A F 06 Abacavir C 01 E B 10 Adenosine L 02 B X 01 Abarelix N 05 B A 07 Adinazolam L 04 A A 24 Abatacept V 08 A C 04 Adipiodone B 01 A C 13 Abciximab N 06 B X 17 Adrafinil L 04 A A 22 Abetimus A 01 A D 06 Adrenalone B 02 B C 01 Absorbable gelatin sponge B 02 B C 05 Adrenalone C 01 E B 13 Acadesine L 04 A B 03 Afelimomab N 07 B B 03 Acamprosate A 16 A B 03 Agalsidase alfa A 10 B F 01 Acarbose A 16 A B 04 Agalsidase beta C 07 A B 04 Acebutolol A 11 A H Agents for atopic dermatitis, excluding C 07 B B 04 Acebutolol and thiazides corticosteroids S 01 E B 08 Aceclidine N 06 A X 22 Agomelatine S 01 E B 58 Aceclidine, combinations C 01 B A 05 Ajmaline M 01 A B 16 Aceclofenac B 05 X B 02 Alanyl glutamine M 02 A A 25 Aceclofenac N 06 A B 07 Alaproclate R 03 D A 09 Acefylline piperazine P 02 C A 03 Albendazole M 01 A B 11 Acemetacin B 05 A A 01 Albumin B 01 A A 07 Acenocoumarol A 07 X A 01 Albumin tannate N 05 A A 04 Acepromazine
    [Show full text]
  • List of Off-Patent, Off-Exclusivity Drugs Without an Approved Generic
    List of Off-Patent, Off-Exclusivity Drugs without an Approved Generic To improve transparency and encourage the development and submission of abbreviated new drug applications (ANDAs) for drugs with limited competition, FDA is publishing a list, consistent with the methodology described below, of approved new drug application (NDA) drug products that are off-patent and off-exclusivity, and for which the FDA has not approved an ANDA referencing that NDA drug product. Part I of the list identifies those drug products for which FDA could immediately accept an ANDA without prior discussion. Part II identifies drug products for which ANDA development or approval may raise potential legal, regulatory, or scientific issues that should be addressed with the Agency prior to considering submission of an ANDA. The Appendix identifies NDA drug products that were removed from Part I or Part II of the list because one or more ANDAs referencing such NDA drug products have been approved since the previous list publication. Sponsors wishing to pursue approval of ANDAs referencing drug products identified in Part II of this list generally should submit an initial inquiry to the Office of Generic Drugs at [email protected]. Sponsors may be referred to the Office of New Drugs under certain circumstances, for example if the product is a biological product, or if the product is not eligible for submission or approval as an ANDA but may be considered for submission under another abbreviated approval pathway. Sponsors should identify the product’s established name and NDA number in any inquiry. • For some products in Part II of the list, submission and/or approval of an ANDA via the 505(j) pathway may not be appropriate; section 505(b)(2) of the FD&C Act may be an appropriate abbreviated approval pathway for such products.
    [Show full text]